1 Min Read
Aug 18(Reuters) - CELLECTIS SA:
* ANNOUNCED ON THURSDAY, UCART123’S ADMINISTRATION TO FIRST PATIENT WITH BPDCN IN PHASE I CLINICAL TRIAL AT MD ANDERSON CANCER CENTER
Source text for Eikon:
Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.